# KPV

> KPV is a tripeptide (Lysine-Proline-Valine) representing the C-terminal fragment of alpha-melanocyte-stimulating hormone, retaining much of the parent molecule's anti-inflammatory activity without its pigmentation effects. It has been studied primarily in animal models of inflammatory bowel disease, colitis, and skin inflammation. Research interest centers on its apparent ability to suppress pro-inflammatory signaling without the broader hormonal effects associated with full-length alpha-MSH. Human clinical trial data remain limited, and KPV is not an approved pharmaceutical therapy.

- URL: https://www.lifeconverted.com/peptides/kpv
- Primary category: Anti-Inflammatory
- Effectiveness rank: #4 in Healing & Recovery; #10 in Immune & Anti-Aging; #3 in Anti-Inflammatory; #5 in Skin & Cosmetic
- Evidence level: Emerging research
- Route: Subcutaneous
- Dose range: 200-1,000 mcg
- Dose tiers: low 200 mcg; moderate 500 mcg; high 1000 mcg
- Half-life: Short, estimated at under 30 minutes, consistent with other small unmodified tripeptides
- Timing: Morning, or split AM/PM
- Cycle: 4-8 weeks on, 4 weeks off (Often used during active flares of inflammatory symptoms rather than continuously)
- Storage: Store lyophilized peptide frozen; reconstituted solution refrigerated and used within 2-3 weeks

## Mechanism of action

KPV appears to inhibit nuclear factor kappa-B (NF-kB) signaling, a central regulator of pro-inflammatory gene expression, reducing downstream production of cytokines such as TNF-alpha and IL-6. Unlike full alpha-MSH, KPV does not require melanocortin receptor engagement for many of its effects, suggesting an additional receptor-independent anti-inflammatory pathway. It has also been studied for direct antimicrobial activity in some models.

## Reported benefits

- Studied in animal models of colitis and inflammatory bowel disease
- Explored for skin-related inflammatory conditions
- May help modulate NF-kB-driven cytokine production
- Investigated for supportive wound-healing effects alongside inflammation control

## Reported side effects

- Injection site irritation
- Limited human safety and long-term data
- Theoretical gastrointestinal effects with oral or compounded forms
- Rare hypersensitivity

## Common protocols

- Daily subcutaneous dosing during symptomatic periods
- Combined with healing-focused peptides in compounded research blends

## Stacking notes

Frequently discussed alongside BPC-157 for combined gut-healing and anti-inflammatory research protocols

---

Educational information only, not medical advice. Full disclaimer: https://www.lifeconverted.com/disclaimer